A new Beginning..., page-2394

Currently unlisted. Proposed listing date: 4 SEPTEMBER 2024 #

First 2394 Last

Share
Profile

Follow
AlCp

27,364 Posts.

1777

04/02/19

23:34

Post #: 37328687
Share

Originally posted by Southoz ↑

All good Red bar. You’re a good advocate for RAP … and argue the substantive points.

A couple of things …

No not one of the illnesses was superior to 68.6 (look at lower bound of the 95% CI). You are actually saying non-inferior to 68.6.

The FDA will model the non-analysable; and run a worse-case scenario. This is to reflect the equivalent of an intent to treat analysis. A doctor doesn’t have the luxury of only diagnosing “analysable” people. To see how this modelling works in practice have a squiz at the IDx Nature paper (and the good editorial):
https://www.nature.com/articles/s41746-018-0040-6

RAP have not stated anywhere the results from the second US trial will be published in a medical journal.

The US investigators (MGH or elsewhere) have not publicly uttered one single word about the results. This is pretty unusual for "good" trial results.

You lost me on where or how you work out what the analysis of cough sounds adds to the predication. If someone was to say it is zero … where do you work out this is false.

In terms of this “good as clinical diagnosis accuracy” argument. The study wasn't designed to measure clinical diagnosis in routine practice.

Getting poor inter-rater reliability between your adjudicators simply suggests that you have failed to specify diagnostic criteria properly … or have over-worked, under-paid or rogue personnel. It isn’t actually a reason for lowering your bar from where you originally thought accuracy for clinical significance lay.

Particularly when the illness that was arguably best specified – pneumonia - using WHO PEP standards) had one of the worst outcomes.

Just as a complete aside (blokey) … I made one post on FFT before the failed trial results; sentiment none – not held. Hardly say “wrong” – more like it didn’t go the way I hoped it would.

https://hotcopper.com.au/threads/an...er-meets-biotech-perth.4363960/#post-35077886

But anyway it will be interesting if RAP stay the course arguing the results were good and have a crack at the FDA.

Expand

True, only Breathe Easy has.....hence, the CE submission is more advanced.

"Detailed results from the Australian Breathe Easy study have recently been submitted for publication in a peer-reviewed medical journal."

RAP Price at posting: 10.0¢ Sentiment: Buy Disclosure: Held
Upvote

0 Great analysis

Reply

Top Stories

The winners & losers on market if negative gearing were gone

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

The market's shrugged at China's stimulus measures all year. Why is this one different?

DEG

HotCopper users muse on De Grey's denial of Agnico Eagle takeover bid – but who are Agnico?

STK

5.6g/t gold intercept at Serbia's Rogozna supports Strickland's hopes for high-grade core

KAL

KalGold rolls out detailed aeromagnetic survey across Pinjin project

Week 39 Wrap: What HotCopper’s watching; China’s new stimmy moves boost metals; Oz CPI drop

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

NAM

ACCC seeks Olam divestments before it can buy Namoi Cotton

ESR

Estrella first foreign entity to win tenements in Timor-Leste under new laws ahead of 2025 tenders

There are more pages in this discussion • 1,055 more messages in this thread...

First 2394 Last

Add RAP (ASX) to my watchlist

A new Beginning..., page-2394

Top Stories

The winners & losers on market if negative gearing were gone

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

The market's shrugged at China's stimulus measures all year. Why is this one different?

HotCopper users muse on De Grey's denial of Agnico Eagle takeover bid – but who are Agnico?

5.6g/t gold intercept at Serbia's Rogozna supports Strickland's hopes for high-grade core

KalGold rolls out detailed aeromagnetic survey across Pinjin project

Week 39 Wrap: What HotCopper’s watching; China’s new stimmy moves boost metals; Oz CPI drop

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

ACCC seeks Olam divestments before it can buy Namoi Cotton

Estrella first foreign entity to win tenements in Timor-Leste under new laws ahead of 2025 tenders

Featured News